Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dilution to make your head spin. Long shares are about to get raked over the coals beyond the 2 to 1 and 100 to 1 reverse splits.
Offering Price lowered and Shares/Warrants increased. Additional 500,000 Shares + 500,000 Warrants for public offering and underwriters. 8M Capital Raise to 8.4M Capital Raise.
Total Shares + Warrants up for grabs - 4,363,984
Current Outstanding Shares - 1,674,868
Current Warrants - 527,770
Outstanding Shares after public offering - 3,856,860
Warrants after public offering - 2,709,762
Fully Diluted Shares - 6,566,622
Form F1/A
Amendment #4 - Filed April 25 2022
1,684,210 Units, each Unit Consisting of One Common Share and one Warrant to Purchase one Common Share
1,684,210 Pre-funded Units, each Pre-funded Unit Consisting of one Pre-Funded Warrant to Purchase one Common Share and one Warrant to Purchase one Common Share
We will sell these Units at a public offering price of US$4.75 per Unit.
Each Warrant will entitle the holder to purchase one Common Share at an exercise price of 110% of the price of the Units in this offering
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322010694/formf1a.htm
Form F1/A
Amendment #5 - Filed May 9 2022
In December 2021, we became a remote-first company. Accordingly, we do not currently maintain a headquarters.
1,931,922 Units, each Unit Consisting of One Common Share and one Warrant to Purchase one Common Share
1,931,922 Pre-funded Units, each Pre-funded Unit Consisting of one Pre-Funded Warrant to Purchase one Common Share and one Warrant to Purchase one Common Share
...based on an assumed offering price per Unit of US$4.348, the last reported price of our Common Shares as reported on the OTC Market Group Inc.'s Venture Market (the "OTCQB") on May 5, 2022. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of 110% of the price of the Units in this offering
We have granted the underwriters a 45-day option (commencing from the date of this Prospectus) to purchase up to an additional 289,788 Common Shares and/or up to an additional 289,788 Warrants at the public offering price per Common Share and per Warrant respectively
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322011852/formf1a.htm
FWP (Prospectus) - Filed May 10 2022
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322011950/formfwp.htm
A free writing prospectus (FWP) is a written communication regarding securities being publicly offered disseminated by the issuer during the waiting period of an initial public offering (IPO) that discloses information that would not be included in the registration statement.
https://www.law.cornell.edu › wex
M$ comment:
Longs holding pre-split shares will need a Market Cap of $200M USD to break even. Basically dead money here for the foreseeable future. As I see nothing in the pipeline to get to that valuation prior to a standalone clinical trial for Chronic Cough with stat SIG results better than Bellus Health. Meanwhile, the walls around Algernon appear to be on fire but for the fact the company no longer has a corporate office. Pure insanity with Moreau's prior BS decisions and timelines driving the company over every cliff imaginable. Moreau stated his goal was to provide shareholders with "Life-changing" returns on their investment. Uhh ok. In what lifetime - this one or the next? A standalone Chronic Cough Phase 3 clinical trial should already be underway. It's the best shot at success purchased by shareholders back in 2018. Christopher Moreau is unequivocally the absolute worst "CEO" ever.
Stay tuned
https://algernonpharma.com/
Recap: Hey Cart! Folks would love to see a snapshot of all the money being made by holding this POS.
Let me know if you understand the question or simply can't answer it.
Of all the stocks to buy during the market meltdown it surely wouldn't be a historical king flipper cse/otc stock.
FN classic stocks with market caps more than 50% shaved off in recent weeks are sure to rebound by Q4. Those are the targets, but WTF ever.
Someone's gotta keep swimming in muddy waters with the guppies.
M$
At this snail's pace to uplist, I wouldn't be surprised if bonehead scrapped the whole story and simply did another CSE private placement for around $2 per share - 4 million shares + 4 million warrants. Run it all to hell at 10 million shares outstanding after warrants exercise at $2.75 per share. I put nothing past the evil that men do.
Surely, no one's listening to/taking seriously the CEO. Thus, I'd love to hear a single word ever come out of the mouth of the Chairman Of The Board regarding Algernon Pharma-ceuticals future outlook.
Meanwhile, someone please tell Beer Buddy I said hell/low.
M$
Do yourself some real Due Diligence here:
They continue to move their arbitrary timeline for detection. The less time of detection the worse chance of trying to determine impairment. Meaning, Cannabix is getting down to a window where no cops will be able to use the data unless they catch someone literally smoking behind the wheel.
Also, if you think parts per billion is as accurate as parts per trillion have at it. However, it goes directly to the issue of accuracy. Funny how they now tried yet another version of detecting thc. One should assume that means they are still searching for how to make the FAIMS tech work. The smoke and mirrors at Cannabix remains foggy at best.
That fake 40 cent wall targeted at newbies is the only thing holding it up.
Not good sir.
M$
Understand where you stand in the pecking order.
The higher the level of sensitivity - the more accurate the measurement for whatever molecules are being targeted.
Cannabix - "...and various VOCs in urine, breath, and other matrixes [50]. The ion mobility spectrometry technique has a reported detection limit of 12.5, 25, and 65 parts per billion (ppb) for methamphetamine, amphetamine, and ?9-THC, respectively"
https://www.researchgate.net/figure/a-Breath-collection-unit-for-cannabis-testing-by-Cannabix-Technologies-Inc-reproduced_fig1_337965190
Vox - "This groundbreaking detection technology will be a highly compactable and portable device that can detect and measure VOCs (Volatile Organic Compounds) in part per trillion."
https://voxbiomedical.com/vox-biomedical-featured-as-top-law-enforcement-solution-providers-in-2021
Hound - "Identifying recent marijuana use in breath requires measuring parts per trillion, which would be like finding 1 person in the population of 142 earths combined"
https://houndlabs.com/product-overview/
Unlike HL and Vox, you can't even find Cannabix's level of sensitivity (parts per billion) actually on their website. If it is there it's like finding a needle in a hay stack. They probably rather you not know. Kinda like Cannabix's top advisor Dr. Marilyn Huestis trying to rip on Hound Labs about their devices level of sensitivity. Huestis was thoroughly debunked by the clinical trial data peer-reviewed and published for all to see.
Until the next pump...
Peace
M$
...yeah they've been BLO-ing since 2015 right?
Keep in mind they are conducting study after study.
It's not clinical trials.
BIG DIFFERENCE IN THE REAL WORLD.
https://houndlabs.com/product-research/
M$
Regarding the latest NR: If you throw out all the fancy pansy mumbo jumbo words only a scientist could understand along with their dreamy naming of their instruments, it all boils down to a nothing burger. They are simply saying the crap testing they've conducted using their initial thc testing method has now flipped into using yet another different thc testing method. What that tells me is they know their testing has remained inadequate for real word applications. Just like the window of detection remaining wishy washy at best. That news release is a hit mess. They talk about 1hr 40 minutes of detection then throw in a 4 hr window of detection to cover all the bases. Which is it? Cannabix remains an overbought pump company. Nothing more. So don't focus on my interpretation of their latest attempt to convince you otherwise. What's your understanding of their tech and where it stands? Meanwhile, I'll see you at the next gas/lighting pump.
M$
“The man called his wife’s name Eve, because she was the mother of all living.” – Genesis 3:20
On Tomorrow: Happy Mother's Day To All Mother's In This Life & The Afterlife
On Tomorrow: Happy Mother's Day To All Mother's In This Life & The Afterlife
On Tomorrow: Happy Mother's Day To All Mother's In This Life & The Afterlife
Common Sense 101
Facts are not a hard thing to come by if one is seriously interested in finding facts versus filtered fiction. The fact of the matter is you never go to clinicaltrials.gov to follow the latest information coming directly out of the CEO's mouth. You go to the corporate website.
News Release:
...The Company is projecting a data readout in calendar Q2, 2022.
“We are very pleased to announce this update to the market on our IPF and chronic cough study and we look forward to having it completed and presenting the data,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
https://www.globenewswire.com/news-release/2022/02/04/2379200/0/en/Algernon-Pharmaceuticals-Announces-Completion-of-Enrollment-in-its-Phase-2-Study-of-Ifenprodil-for-IPF-and-Chronic-Cough.html
As I stated, management missed yet another quarter just like the pipeline illustration as well.
See IPF/CC "Data - Q2 2022"
Expect Final Data no earlier than Q4 2022.
Just in time for your Annual (Anal) lump of coal stocking stuffer.
CJM IS The Grinch Who Steals Christmas
Just facts,
M$
Postscript
For arguments sake, I read 55's post at Yahoo. He illustrated an "update" regarding the IPF/CC clinical trial. The update is dated March 2022. Now look at the date of the above news release. What would have materially changed from February to March that would suggest Moreau didn't know when data would be available to the public for another quarter (Q2 now Q3)? The bottom line is management missed another quarter to report data from a clinical study that's been fundamentally flawed from the outset.
4D Outro
Think Outside The Box
@ algernonpharma.com
Play The Card You've Just Been Dealt
Management misses yet another Quarter in releasing data.
“We are pleased to be coming closer to this value inflection point in our Phase 2 clinical trial for IPF and chronic cough, both debilitating conditions with limited treatment options,” said Christopher J. Moreau, CEO of Algernon.
Value Inflection Point? ROTFLMAO. When have we heard Moreau say that line before - the COVID-19 Topline & Final Data flops? Yeah, ok. Where's Andre Uddin when you need a 20 Cents per share ($2 post "consolidation") analysis of the data? You can now expect a nothing burger final data readout not in Q2 or Q3 but in Q4 2022.
M$
55 - "...A Big Splash entering the NASDAQ"
Yeah, it's no longer about Christopher Moreau's "Everybody Wants In At Phase 2."
Now it's - Everybody Wants In At Phase 1.
Is Moreau's infamous quote suppose to be a clever idiom or merely a line made up for idiots?
After dilution the Market Cap will need to be well north of $150M USD @ $30 per share to break even on the pre-consolidation of shares (100 to 1 Reverse Split) - lest you ever forget.
Big Splash
M$
rotflmao...if that's still allowed.
at the end of the day...the only game being played is shareholders.
hahahahaha
M$
CSE + OTC = Bipolar Market Makers
BLOZF + AGNPF = Team Cobra/Clown Team
algernonpharmaceuticals.com + algernonpharma.com = Smart Business
NASDAQ Uplist + Standalone Chronic Cough Clinical Trial In USA = only real chance of success for common shareholders
Bellus Health + Algernon Pharmaceuticals = Winners versus Losers
Carry on...
https://investorshub.advfn.com/uimage/uploads/2022/5/3/vxfvhistockphoto-185919303-612x612.jpg
M$
Anyone else claiming to be confused?
Shareholders with real money (not lunch money) that vanished like magic under the Big Top certainly are not confused. The Clown Team has a remarkable ability to waste money and time. Thus, I'll remind any confused shareholders the very last so-called clinical trial @ AlgernonPharma (AP) was launched back in July of 2020 and still pending a 20 patient data readout.
The 1st truly powered for stat sig "Everybody Wants In @ Phase 2" clinical trial will likely not conclude until 2025 or 2026. In such time, I expect AP to follow the same path as Xortx. Moreau had already signalled he plans to follow in Xortx footsteps. Moreau hired their former CEO (sheesh). Look at Xortx pathetic performance since uplisting to Nasdaq - Market Cap: 17M USD
Yet another losing strategy @ AlgernonPharma
M$
My point about Nutt and management stands without trying to confuse the matter here in fly over country.
As always ...I offer real world due diligence. I've never been a stowaway barking from the cargo area.
I'm guessing flyover country has finally moved on from the ridiculous baggage claims about waiting for this that or the other tests to reap some kind of benefit before a capital raise.
However, I assume it will always be some kind of testing this that or the other thrown in the mix to make excuses for managements non-stop failures to execute.
Simple sh!t to understand in pennyland ain't complicated. Which is why Algernon remains stuck on the runway.
Geez Us...I'm tired of holding passengers hands.
M$
Somebody please let me know when Cannabix will EVER conduct actual human Clinical Trials to validate any of it's technology. If it doesn't seem strange that Hound Labs has done just that and Vox Biomedical maybe something is seriously wrong with your due diligence efforts.
https://voxbiomedical.com/investors
TGIF
M$
Algernon's "DMT Stroke Consultant" Dr/Professor David Nutt (a London resident) will be at the largest gathering of global Psychedelics experts to date in London on May 11 2022. There will likely be zero mention of Algernon because Dr. Nutt will be there to represent Compass Pathways. Yet another opportunity missed by the clown team at Algernon.
https://www.benzinga.com/markets/cannabis/22/04/26886825/a-landmark-gathering-of-psychedelics-executives-and-scientists-arrives-in-london-on-may-11
Stone Age to \|/ Stone
One question I have for management is why in the world would you spend millions of dollars in the name of "advertising" and goo gobs of "infomercials" with the CEO's face plastered everywhere on the website in support of such infomercials (reminder of the spend rate) and the stock only continues to veer towards new all time lows at every turn? Ok, so now management made it's pitch and delivery on moving to Nasdaq with the belief the company will be exposed to a better classroom investors. Given that execution, what roll should their website play in the grand scheme of things?
Business 101 suggests you can drive more eyes to your website with the minimalist number of characters. 14 characters or less is the best target zone to accomplishing maximum drive/traffic. Therefore, why didn't management secure the most obvious website for the company moving forward with the rebranding of the company in 2018? Moreau spewed reels of infomercial stories about how he came up with the Algernon name and how he needed to convince Dr. Mark Williams (The Brainchild of All Things in Algernon's Pipeline Portfolio) it was a good idea. Ok, but again why did you not think or think at all it was a good idea to secure the shorter and more desirable domain name for the company from the outset for $10 freaking dollars! If you go out to Algernon's Twitter page the first thing you will see below the corporate logo at the top of the page is "AlgernonPharmaceuticals@AlgernonPharma.com". Do you see where the Pharma is abbreviated there? Surely, it proves a shorter version of the word Pharma is more desirable in their minds eye. Think of how hard is is for some to correctly spell the name Algernon and then how much harder it's likely to spell Pharmaceuticals. You have two words combined that are both hard to spell and twice as challenging for the average speller. There could be an argument made for Algernon not being hard to find on the web, but I'd contribute that to it currently being zero competitive traffic for the better version of a corporate domain name - algernonpharma.com.
The company has no control over that more effective version and what could be potentially trafficked to that website if it every becomes active on the web. If it were to become a space that is not complimentary to Algernon's corporate narrative I could see that posing legal expenses that surely would not be cheap. Thus, management needs to seriously consider what they want to control for it's messaging to the masses and the cost to doing their homework now versus compounding after the fact actions not in their favor.
Here's something else I found interesting in the world wide web realm. Algernon will list at nasdaq with a new abbreviated version of it's stock ticker. From AGNPF to AGNP. Less is better! Now do a web search for AGNP.com. What I gather is someone is targeting a specific company to buy their domain name at a price that suggests they mean business and have done their potential homework an advance of the offering. I firmly believe it has absolutely nothing to do with Algernon Pharmaceuticals but who knows? The bottom line is management need not be hardheaded and stubborn for fumbling the ball in regards to completely missing the mark for securing domain names (they should have secured both long and short version) from the outset. Moreau should check his pride at the door and do what needs to be done in this regard. They've already spending money on "ads" like drunken sailors. Make a real difference with your 21st Century Corporate B R A N D I N G. The better domain name is just Business 101. Management needs more savvy people for the upkeep of their corporate website/image.
Mark this post.
M$
New F-1/A filing: @ $4.75 USD - Shares are going to more than double with matching warrants that will more than triple the outstanding shares to raise $8,000,000 USD. You are looking at 5 Million+ Fully Diluted Outstanding Shares at the in-the-money stock price of $5.23 USD.
5 Million Shares @ $5.23 USD = $26 Million USD Market Cap.
The company is effectively selling 100 to 1 reverse split shares @ 4 Cents per share. That's what the pending capital raise represents in real world terms for current shareholders.
I'm of the belief today's news release is to circumvent/camouflage/give cover to the latest plan. It was 9 million bid for capital now 8 million bid for capital.
It's my belief that break even for most 100 to 1 pre-reverse split shares is 30 Cent USD. Therefore, at 5 Million Outstanding Shares the company needs a market cap of $150 Million USD/$30 per share.
https://ih.advfn.com/stock-market/USOTC/algernon-pharmaceuticals-qb-AGNPD/stock-news/87896244/securities-registration-foreign-private-issuer-f-1
Best guess is AGNPF will see $2 per share again this year.
M$
You can take away the name Twitter and Social Media and replace them with Algernon and Biotech.
It's 4.5 cents for most portfolios not $4.5 USD.
Let me know when the stock is holding above $30 USD which is effectively 30 Cents.
M$
You're making up your own conclusions about the 50/50 FAIMS tech. I've consistently said I believe the FAIMS is inferior to the competition. A reason why it remains in a prototype status indefinitely. The point of the 50/50 issue is the tech was pulled out from under shareholders at Algernon. It happened around the same time Algernon's CEO (Christopher Moreau) and CSO (Mark Williams, PhD, MBA) was on the payroll at now failed - First Responder Technologies. Yeah, Algernon's top management was beholden to the whims of Cannabix's "President" and Director because Kulwant Mahli was the Chairman of the Board at First Responder Technologies around such time. I believe it was the same year the CEO of Algernon put together a compensation package for himself north of 1 million dollars. Imagine that...a Million dollar CEO of a pennyland nano cap company with a market cap of 7 Million dollars just surrendering the FAIMS technology for not a single done or shared of Cannabix for it's years long collaboration. Moreau has learned the type of bad faith habits that should get anyone Fired, Fined, and/or Perp Walked. So, no to the performance of the FAIMS technology because it all remains mystery meat. You don't really have a clue about what you supposedly own from a working breathalyzer perspective. Cannabix will be dilly dallying around with something else shiny and new to you in the coming months and years. Don't get tied up in knots because I speak the truth of the matters. Attacking me does nothing for your cause - a lost cause IMO. Stories is what Cannabix and Algernon offer year after year to shareholders. Thus, I'm telling their story.
2077 is the year of Cannabix's time to shine.
M$
Projection? You're the funny one. I'm a realist.
Yo Fushion...what else you got?
M$
What I'm telling you is Cannabix is desperate to keep the story going to prevent the stock from dropping to it's true value of sub 20 cents. You have been waiting forever to get some type of feedback as to your thc contraption working with humans. If you follow the path taken by the company that recently struck gold with it's COVID breathalyzer, reasonable minds would wonder why Cannabix didn't follow a similar path. Like running a true blue clinical trial with their contraption. Doing something like that leaves no doubt about the the efficacy and accuracy of such a device intended for screening of humans. Instead, Cannabix hits you over the head with a narrative about a secret project they have been working on for who knows how long and the details will remain mystery meat for the foreseeable future. Just great...another "thing" to have swirling around in your head as if it has monetary value. So now Cannabix is in the alcohol business. That sounds very similar to the early predictions by some that Cannabix will continue shifting the narrative until you have no idea why you originally invested anywhere along the line of 8 years and counting as Cannabix tries tries and tries again. Meanwhile, you can point to other companies moving past Cannabix and it will only get worse as time rolls on.
Now ask yourself this...why would any company seriously pursuing a thingamajig for breath detection of BAC reach out to a tiny penny stock company with limited resources versus an establish company already in the Alcohol breathalyzer business? What I gather is the mystery auto parts company is a friend of one or more of the insiders. As I've stated, that Tier 1 company could be a guy with 10 employees running an operation out of a pole barn for all you know. The secret agreement situation is pure BS. You have money being spent on shiii without your knowledge, input, or consent. You are caught up in the story of it all. There are no finite timelines for anything at Cannabix. They merely tack on another story to chase after in your mind - like Germany! Whatever happened to the Breath capture contraption that looks like a hair dryer that attaches to a black box? Yeah, that's the device Cannabix was working on in monetary collaboration - 50/50 with Algernon Pharmaceuticals (formerly known as Breathtec Biomedical). I'm surprised Cannabix have yet to announce the hair dryer device will be used to detect COVID-19 and/or other shiii. The same shiii Breathtec Biomedical set out to do under the same "leadership" as Cannabix's "President" and Director - Kulwant Malhi. At the end of the day Cannabix is good at telling stories like Disney. Unfortunately, all those stories should be filed in the fiction section of the written word spectrum.
M$
I agree. They (board of directors) are not worth it. Christopher Moreau drew himself a million dollar payday back in 2019. A million dollar CEO of a flailing and failing nano cap company in Penny World. Yeah, ^ that guy. From Pandemic to Recession to WWIII. Who cares about timelines? We're all gonna live forever!
Over The Cl!ff Crazy Ch!t @ Algernon Pharmaceuticals Inc.
M$
Outro
Another story to pump with an agreement with a ghost company. Surely, that gives the cult endless theories for another 10 years. Everything at Cannabix remains in a perpetual state of prototype development and testing. You can patent a ham sandwich. It doesn't equate to monetization. Also, filing for a patent doesn't equate to a patent approval. The last time I checked, Cannabis takes more than 5 years to navigate the patent process. Let history be your guide and expect no less a time frame if ever.
Enjoy another pump...
The crazy part of the story is these two guys started out targeting a marijuana breathalyzer and switched gears to a medical breathalyzer for COVID-19. They have successfully done EGG ZACK LEE what shady leadership of Breathtec/Algernon set out to do in the beginning (Circa 2016). Which is chase after medical diseases. What shareholders got in return is a now flailing about virtual reality repurposed drugs nano cap (under $50M USD market cap) dilution machine stuck in pennyland. The successful startup company will circle back to the marijuana breathalyzer originally targeted. They will likely succeed where as Cannabix remains in prototype mode 8 years and counting. The value of Algernon lies within the value of the mindset of Algernon's management team. A team that has proven itself worth less and less as time rolls on. Algernon's medical device now lies in the hands of Cannabix under another name - in name only. You can bet Team Cobra will do what it can to mimic the successful start up with new stories down the road about detecting anything other than marijuana. The creative storytellers surrounding Team Cobra will surely strike (snake bite) a slew of newbies again and again.
Meet The Founders Of The $2.7 Million Startup Behind The New Covid Breathalyzer
www.forbes.com/sites/katiejennings/2022/04/15/meet-the-founders-of-the-27-million-startup-behind-the-new-covid-breathalyzer/?sh=59cf3cdc5165
Telling stories, diluting shareholders, and running out the clock is job #1 for Team Cobra.
M$
Retired Psychologist? EOM
rotflmao...you can dismiss all other tech all you want. However, TIME has a way of bringing reality to your boxing corner. It's gonna be a one two punch to the gut for Cannabix. As it's now 2 competitors (a tag team) that will be actively pursuing revenues in 2022.
No boo hoo
Just do you
I do
True,
M$
Postscript
Cannabix been @ it 8 Years!
Outro II
Yo Carthnel! Let me know what you think of the insider transactions over the past 3 6 12 months. Does it exude confidence or a con?
stockhouse.com/companies/insiders?symbol=c.blo
You decide,
M$
Yo Carthnel! There will be plenty of news coming from around the bend. However, it likely won't be news you can use to pump Cannabix Technologies Inc. I mean, that's if you're not content with receiving simple minded updates from Cannabix every other month about testing testing and more testing. So far, you've gotten 8 years of just that.
Behind The 8 Ball
OAN: Go back to my previous post about the COVID-19 breathalyzer company. It's a startup company that brought a device to market in 4 years time. That's after running real world clinical trials that verified their device and accuracy in the 90 percentile. Now that's a company that knows what the hell they are doing for it's investors versus themselves.
M$
FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples
"InspectIR expects to be able to produce approximately 100 instruments per week, which can each be used to evaluate approximately 160 samples per day. At this level of production, testing capacity using the InspectIR COVID-19 Breathalyzer is expected to increase by approximately 64,000 samples per month."
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-diagnostic-test-using-breath-samples
Detection is an Essential Step on the Path to Enforcement & Control:
"With an increased awareness of the opioid epidemic combined with the legal spread of medical and recreational cannabis; the ability to accurately test individuals via a mobile, portable, or roadside device is not currently available.
InspectIR Systems, LLC (IR) is a research, development and device company focused on non-invasive portable detection tools to identify recent opioid and/or cannabis usage."
https://inspect-ir.com/
https://www.prnewswire.com/news-releases/inspectir-systems-closes-seed-round-of-funding-300965642.html
Hound Labs, Inspect IR, both are getting it done in the real world versus endless pennyland stories.
I expect there are other Dark Horses out there who will come to the fore with their technologies as well.
It's gonna be a crowded field if any 1st Mover establishes tangible revenues.
Tic Toc
OAN: Yo 55! Are you STILL trying to make a case for a medical breathalyzer device by Algernon?
SERIOUSLY?
M$